Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)

Molecular Formula	C₁₁H₁₇ClN₄O₄
Molecular Weight	304.73 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	304.0938327 g/mol
Monoisotopic Mass	304.0938327 g/mol
Topological Polar Surface Area	98.8 Å²
Heavy Atom Count	20
Formal Charge	0
Complexity	404
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

1 of 6
Drug Name	Dexrazoxane hydrochloride
PubMed Health	Dexrazoxane (Injection)
Drug Classes	Cardioprotective Agent, Dermatological Agent
Active Ingredient	Dexrazoxane hydrochloride
Dosage Form	Injectable
Route	Injection
Strength	eq 500mg base/vial; eq 250mg base/vial
Market Status	Prescription
Company	Mylan Institutional; Eurohlth Intl

2 of 6
Drug Name	Totect
Active Ingredient	Dexrazoxane hydrochloride
Dosage Form	Injectable
Route	Injection
Strength	eq 500mg base/vial
Market Status	Prescription
Company	Biocodex

3 of 6
Drug Name	Zinecard
PubMed Health	Dexrazoxane (Injection)
Drug Classes	Cardioprotective Agent, Dermatological Agent
Drug Label	ZINECARD (dexrazoxane for injection), a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration.Chemically, dexrazoxane is (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2
Active Ingredient	Dexrazoxane hydrochloride
Dosage Form	Injectable
Route	Injection
Strength	eq 500mg base/vial; eq 250mg base/vial
Market Status	Prescription
Company	Pharmacia And Upjohn

4 of 6
Drug Name	Dexrazoxane hydrochloride
PubMed Health	Dexrazoxane (Injection)
Drug Classes	Cardioprotective Agent, Dermatological Agent
Active Ingredient	Dexrazoxane hydrochloride
Dosage Form	Injectable
Route	Injection
Strength	eq 500mg base/vial; eq 250mg base/vial
Market Status	Prescription
Company	Mylan Institutional; Eurohlth Intl

Find Dexrazoxane manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

14 API Suppliers

9 USDMF

1 JDMF

3 EU WC

5 NDC API

7 Listed Suppliers

DEVELOPMENTS

2 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

13 FDF Dossiers

9 FDA Orange Book

3 Europe

1 Canada

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 250MG BASE/VIAL

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Actylis

DIGITAL CONTENT

4 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 Finished Drug Prices

MARKET PLACE

3 APIs

2 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 Others

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

FINISHED DOSAGE FORMULATIONS

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

1EXCIPIENTS BY APPLICATIONS

01

02

03

04

05

06

07

08

09

10

What are you looking for?

INJECTABLE;INJECTION - EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons